Outcome of the Board Meeting held on Saturday, February 14, 2026 at 05:00 P.M through Video Conferencing (VC)
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fredun Pharmaceuticals filed three related disclosures after its Feb 14, 2026 board meeting: outcome of the meeting, a Statement of Deviation, and CARE Ratings' Monitoring Agency Report on the use of proceeds from its Preferential Issue of equity shares and convertible warrants (issue size ~₹149.50 crore). Of this, ₹97.78 crore had been received by December 31, 2025, with only ~₹11.14 crore (per CARE) or ₹8.04 crore (per company) deployed during the quarter, leaving ₹86.64 crore parked mostly in HDFC Bank fixed deposits and current accounts. CARE flagged deviations (range 25–50%) including ₹37 crore temporarily routed through a Cash Credit account instead of directly into Current Accounts, ₹1.84 crore of loan/EMI payments classified under Working Capital, ₹0.04 crore EMI classified under Capex, a ₹0.45 crore gap in unutilized-proceeds calculation, inadequate supporting documents, payments against invoices more than a year old, and commingling of funds across multiple bank accounts. The Board and Audit Committee accepted the observations but classified them as procedural/classificatory, denied any diversion or change in stated objects, and said strengthened internal controls and segregation would be implemented going forward.
For shareholders, this is a mixed signal — the company raised large funds (₹97.78 crore received) for brand marketing, capex, R&D, and working capital but spent almost nothing in the quarter, and the independent monitor has formally flagged multiple compliance and documentation lapses around how the money moved between bank accounts. While management insists no funds were misused, the 25–50% deviation range and commingling concerns may weigh on investor confidence and invite sharper regulatory scrutiny in subsequent quarters, even though no dividend, earnings, or rating action is triggered here.